Campylobacter fetus infecting a chronic subdural haematoma in a patient with Human Immunodeficiency Virus: A case report

vaccine given after 12 months during the omicron XBB epidemics to who had received the third dose of COVID-19 vaccine.Methods: A prospective, single-center, open-label, phase 2 study assessing immune responses both humoral and T-cell responses were conducted in those who had received two doses of inactivated COVID-19 vaccines with third or fourth dose of any COVID vaccines (adenovirus vector vaccine Ad26.COV2.S or ChA-dOx1, the mRNA vaccine) and receiving bivalent mRNA COVID-19 (original/BA.4-5)vaccine as a booster dose after 12 months.Immune responses were measured by Anti-Spike IgG (GMFR), Pseudovirus neutralizing assay to ancestral, Omicron XBB strain (GMT 50%NT, GMFR) and IFN-Gamma (mIU/mL, Median) at day 0, 28 and 90.Results: 198 enrolled participants had received bivalent mRNA COVID-19 vaccine.190 of 198 were analyzed.57, 66 and 67 participants had previously received third dose with Ad26.COV2.S, ChA-dOx1 and mRNA COVID-19 vaccines respectively.There were no safety concerns reported.No reported of COVID-19 symptomatic infection nor received another COVID-19 vaccine within 90 days of follow up.GMFR from baseline to day 28 and 90 were 6.62, 3.36 in Ad26.COV2.S group, 7.81, 4.04 in ChAdOx1 group and 7.52, 4.37 in mRNA group.Pseudo neutralizing antibody GMT (95% CI) against Ancestral strain at day 0, 28, 90 were 193(135-269), 1315(1095-1581), 1527(1260-1850) in Ad26.COV2.S group 189(133-269), 1531(1356-1729), 1694(1485-1923) in ChAdOx1 group 165 (110-248), 1629(1388-1913), 2078(1731-2494) in mRNA group.GMFR from baseline to day 28 and 90 were 6. 55, 7.60 in Ad26.COV2.S group, 7.40, 8.18 in ChAdOx1 group and 8.45, 10.98 in mRNA group.Pseudo neutralizing antibody GMT against Omicron XBB 1.5 strain at day 0, 28, 90 were 28 (14-56), 792(624-1005), 327(263-407) in Ad26.COV2.S group 14(7-28), 867(867-1075), 332(228-483) in ChAdOx1 group 13(6.9-25),1129(951-1340), 475(383-589) in mRNA.GMFR from baseline to day 28 and 90 were 13.04, 5.4 in Ad26.COV2.S group, 20.9, 8.03 in ChAdOx1 group and 29.16, 12.77 in mRNA group.Median IFN gamma day 0, 28, 90 were 1686,

Authors

Publication Details

Journal
International Journal of Infectious Diseases
Published
2025-02-28
DOI
https://doi.org/10.1016/j.ijid.2024.107507
Primary Topic
Amoebic Infections and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Campylobacter fetus infecting a chronic subdural haematoma in a patient with Human Immunodeficiency Virus: A case report

Peter R. Brink, Wentzel Dowling, Kobus Venter, Dr Rosemary Griessel
International Journal of Infectious Diseases
Amoebic Infections and Treatments
article

Campylobacter fetus infecting a chronic subdural haematoma in a patient with Human Immunodeficiency Virus: A case report

Peter R. Brink, Wentzel Dowling, Kobus Venter, Dr Rosemary Griessel
article en

Abstract

vaccine given after 12 months during the omicron XBB epidemics to who had received the third dose of COVID-19 vaccine.Methods: A prospective, single-center, open-label, phase 2 study assessing immune responses both humoral and T-cell responses were conducted in those who had received two doses of inactivated COVID-19 vaccines with third or fourth dose of any COVID vaccines (adenovirus vector vaccine Ad26.COV2.S or ChA-dOx1, the mRNA vaccine) and receiving bivalent mRNA COVID-19 (original/BA.4-5)vaccine as a booster dose after 12 months.Immune responses were measured by Anti-Spike IgG (GMFR), Pseudovirus neutralizing assay to ancestral, Omicron XBB strain (GMT 50%NT, GMFR) and IFN-Gamma (mIU/mL, Median) at day 0, 28 and 90.Results: 198 enrolled participants had received bivalent mRNA COVID-19 vaccine.190 of 198 were analyzed.57, 66 and 67 participants had previously received third dose with Ad26.COV2.S, ChA-dOx1 and mRNA COVID-19 vaccines respectively.There were no safety concerns reported.No reported of COVID-19 symptomatic infection nor received another COVID-19 vaccine within 90 days of follow up.GMFR from baseline to day 28 and 90 were 6.62, 3.36 in Ad26.COV2.S group, 7.81, 4.04 in ChAdOx1 group and 7.52, 4.37 in mRNA group.Pseudo neutralizing antibody GMT (95% CI) against Ancestral strain at day 0, 28, 90 were 193(135-269), 1315(1095-1581), 1527(1260-1850) in Ad26.COV2.S group 189(133-269), 1531(1356-1729), 1694(1485-1923) in ChAdOx1 group 165 (110-248), 1629(1388-1913), 2078(1731-2494) in mRNA group.GMFR from baseline to day 28 and 90 were 6. 55, 7.60 in Ad26.COV2.S group, 7.40, 8.18 in ChAdOx1 group and 8.45, 10.98 in mRNA group.Pseudo neutralizing antibody GMT against Omicron XBB 1.5 strain at day 0, 28, 90 were 28 (14-56), 792(624-1005), 327(263-407) in Ad26.COV2.S group 14(7-28), 867(867-1075), 332(228-483) in ChAdOx1 group 13(6.9-25),1129(951-1340), 475(383-589) in mRNA.GMFR from baseline to day 28 and 90 were 13.04, 5.4 in Ad26.COV2.S group, 20.9, 8.03 in ChAdOx1 group and 29.16, 12.77 in mRNA group.Median IFN gamma day 0, 28, 90 were 1686,

International Journal of Infectious DiseasesVol. 152
Good health and well-being
Openalex Percentile: Top 94%
Amoebic Infections and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.